FDA will distinguish most innovator biologics and biosimilars with a suffix added to their nonproprietary name, but the long-awaited plan leaves some important questions unanswered.
FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach
Most biologics will have random four-letter suffix added to nonproprietary name, but FDA asks a number of questions about potential alternatives.